entinostat has been researched along with Kaposi Sarcoma in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Importantly, in vivo preclinical studies showed that 009P1 and 009P2 dramatically suppressed KSHV+ lymphoma progression with oral bioavailability and minimal visible toxicity." | 1.91 | Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas. ( Chen, J; Chen, Z; Dai, L; Kendrick, S; Li, HY; Lin, Z; Phuc, T; Qin, Z; Wang, Z; Xu, Z; Yang, D, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J | 1 |
| Wang, Z | 1 |
| Phuc, T | 1 |
| Xu, Z | 1 |
| Yang, D | 1 |
| Chen, Z | 1 |
| Lin, Z | 1 |
| Kendrick, S | 1 |
| Dai, L | 1 |
| Li, HY | 1 |
| Qin, Z | 1 |
1 other study available for entinostat and Kaposi Sarcoma
| Article | Year |
|---|---|
Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas.
Topics: Cell Cycle Proteins; Cell Line, Tumor; Herpesvirus 8, Human; Histone Deacetylase Inhibitors; Humans; | 2023 |